Scrutiny Continues to Grow Around the Cost of Specialty Drugs

Marc O'Connor, COO and chief strategy officer of Curant Health, discusses increased oversight of specialty medication pricing.

Related Content:

InterviewsReimbursementSpecialty Pharmacy

Ohio Leads the Way in Pharmacy Reform, Will Other States Follow?

Updates in Prevention, Treatment of Cytokine Release Syndrome, Neurologic Toxicities for Patients With Multiple Myeloma

Study: Ibrutinib Effective Treatment for Difficult to Treat Forms of Hairy Cell Leukemia